Compass Therapeutics Inc.

NASDAQ CMPX

Data sourced from

and

Download Data

Compass Therapeutics Inc. Days Inventory Outstanding (DIO) for the quarter ending March 31, 2024

Compass Therapeutics Inc. Days Inventory Outstanding (DIO) is NA for the quarter ending March 31, 2024. The days inventory outstanding ratio measures the average number of days it takes for a company to sell its inventory. It is calculated by dividing inventory by the cost of revenue and then multiplying by 365. This ratio indicates the average number of days inventory is held before being sold. A lower number of days suggests faster inventory turnover and efficient inventory management.

NASDAQ: CMPX

Compass Therapeutics Inc.

CEO	Dr. Thomas J. Schuetz M.D., Ph.D.
IPO Date	April 5, 2021
Location	United States
Headquarters	80 Guest Street, Boston, MA, United States, 02135
Employees	32
Sector	Healthcare
Industry	Biotechnology

Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Key trends